Text Size

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by:
Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier:
NCT00691028
First received: June 3, 2008
Last updated: May 19, 2013
Last verified: May 2013
History of Changes
Results First Received: January 29, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Rheumatoid Arthritis
Interventions: Drug: TA-650 3 mg/kg
Drug: TA-650 6 mg/kg
Drug: TA-650 10 mg/kg

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
TA-650 3 mg/kg 99 patients received TA-650 at 3mg/kg treatment during the double-blind period starting from week14.
TA-650 6 mg/kg 104 patients received TA-650 at 6mg/kg treatment during the double-blind period starting from week14.
TA-650 10 mg/kg 104 patients received TA-650 at 10mg/kg treatment during the double-blind period starting from week14.
Open-label 327 patients received TA-650 at 3 mg/kg treatment during the open-label period.

Participant Flow for 2 periods

 Period 1:   Open-label Period
    TA-650 3 mg/kg     TA-650 6 mg/kg     TA-650 10 mg/kg     Open-label  
STARTED     0     0     0     327  
COMPLETED     0     0     0     307  
NOT COMPLETED     0     0     0     20  
Adverse Event                 0                 0                 0                 16  
Withdrawal by Subject                 0                 0                 0                 3  
not come to a hospital                 0                 0                 0                 1  

Period 2:   Double-blind Period
    TA-650 3 mg/kg     TA-650 6 mg/kg     TA-650 10 mg/kg     Open-label  
STARTED     99     104     104     0  
COMPLETED     86     91     95     0  
NOT COMPLETED     13     13     9     0  
Adverse Event                 8                 9                 6                 0  
Lack of Efficacy                 4                 3                 2                 0  
Withdrawal by Subject                 1                 0                 1                 0  
not come to a hospital.                 0                 1                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
TA-650 3 mg/kg 99 patients received TA-650 at 3mg/kg treatment during the double-blind period starting from week14.
TA-650 6 mg/kg 104 patients received TA-650 at 6mg/kg treatment during the double-blind period starting from week14.
TA-650 10 mg/kg 104 patients received TA-650 at 10mg/kg treatment during the double-blind period starting from week14.
Total Total of all reporting groups

Baseline Measures
    TA-650 3 mg/kg     TA-650 6 mg/kg     TA-650 10 mg/kg     Total  
Number of Participants  
[units: participants]
 		  99     104     104     307  
Age  
[units: participants]
 		       
<=18 years     0     0     0     0  
Between 18 and 65 years     89     96     92     277  
>=65 years     10     8     12     30  
Age  
[units: years]
Mean ± Standard Deviation 		  49.7  ± 11.7     48.8  ± 11.8     50.4  ± 12.5     49.6  ± 12.0  
Gender  
[units: participants]
 		       
Female     78     86     89     253  
Male     21     18     15     54  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Numeric Index of American College of Rheumatology Response (ACR-N, N Shows the Percent Improvement)   [ Time Frame: baseline and week 54 ]
  Show Outcome Measure 1

2.  Secondary:   Percentage of Participants Achieving American College of Rheumatology 20, 50 and 70% Response (ACR20, 50, 70)   [ Time Frame: 54 weeks ]
  Show Outcome Measure 2

3.  Secondary:   Tender Joint Counts (TJC)   [ Time Frame: 54 weeks ]
  Show Outcome Measure 3

4.  Secondary:   Swollen Joint Count (SJC)   [ Time Frame: 54 weeks ]
  Show Outcome Measure 4

5.  Secondary:   CRP Level   [ Time Frame: 54 weeks ]
  Show Outcome Measure 5

6.  Secondary:   Change From Baseline in DAS28   [ Time Frame: baseline and week 54 ]
  Show Outcome Measure 6

7.  Secondary:   Change From Baseline to Week 54 in HAQ   [ Time Frame: 54 weeks ]
  Show Outcome Measure 7

8.  Secondary:   Change in Modified Total Sharp Score (mTSS) at week54 From Baseline   [ Time Frame: baseline and week 54 ]
  Show Outcome Measure 8

9.  Secondary:   Pharmacokinetics Positive- ATI   [ Time Frame: 54 weeks ]
  Show Outcome Measure 9

10.  Secondary:   Pharmacokinetics- Serum Concentration of Infliximab   [ Time Frame: 54 weeks ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Clinical Trials, Information Desk
Organization: Mitsubishi Tanabe Pharma Corporation
e-mail: cti-inq-ml@ml.mt-pharma.co.jp


No publications provided


Responsible Party: General Manager, Clinical Research Department III, Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier: NCT00691028     History of Changes
Other Study ID Numbers: TA-650-13, JapicCTI-050146
Study First Received: June 3, 2008
Results First Received: January 29, 2013
Last Updated: May 19, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare